Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexagon in Venous Leg Ulcers
NCT01199588Phase 2Completed
- Sponsor
- OcuNexus Therapeutics
- Start
- May 2011
- Primary completion
- Dec 2012
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
A Phase 2 trial of lufepirsen in venous leg ulcer (VLU), sponsored by OcuNexus Therapeutics. Started May 2011; status: completed.
02
Drugs
lufepirsen
03
Conditions
venous leg ulcer (VLU)
Beyond the preview
Go deeper on NCT01199588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01199588.